Group: Team

Ray Reilly

With over 25 years in the research industry, Ray has extensive operational, business, and global clinical development experience. Ray’s roles have spanned the spectrum from gene modification bench science through to CRO and Biotech executive positions. Ray has delivered from FIH studies to pivotal studies leading to product approval. This range of experience enables him

Greg Spalla

Greg has almost 30 years of experience managing Supply Chain Organizations for Global Commercial Pharmaceutical and emerging Biotech Companies. In this past experience, he has had responsibility for distribution, sourcing, forecast planning, purchasing (Direct and Indirect) and worked on numerous commercial product launches of both NDA and ANDA products, as well as a rich pipeline

Karen Bruckmann

Karen joins Aceragen as Senior Director Clinical Operations. She has over 25 years working experience in global CROs, pharma and biotech companies. She brings valuable set of experience in clinical operations, project and quality management. Karen was instrumental in successfully creating and growing the Early Phase Monitoring Department of a global CRO, where she served

Tania Schneilin

Experienced Executive Administrator, Office Manager and Project Coordinator with profound experience in managing offices, working with Senior Management, Medical Affairs and Key Opinion Leaders, in an international environment. After gaining a solid experience in a well-established Cosmetic and Pharmaceutical Company for almost 15 years, Tania started a new chapter and joined the Biotechnology Start-up journey.

Liang Ding

Liang joins Aceragen with CMC analytical and bioanalytical experiences in drug development for rare diseases. Before joining Aceragen, Liang worked at CRISPR Therapeutics, Homology Medicines, and Tessera Therapeutics, where he and his team developed analytical methods to characterize and quality control a range of modalities, Cas9/gRNA, mRNA, lipid nanoparticles, virus, and proteins. Liang is also

Gwen Thomas

Gwen Thomas serves as Associate Director of Business and Project Management. Prior to joining Aceragen, Inc., Gwen worked in varied industries including a Fortune 100 computer company and a K-12 a private school, before delving into the world of pharma. Her first taste was with a pharmaceutical startup developing a drug for cystic fibrosis and

Katie Crosby

Katie joins Aceragen with over 8 years of experience working in clinical care and research for rare diseases. As a board-certified genetic counselor, Katie specializes in supporting patients and families to understand and navigate their genetic diagnoses. Before joining Aceragen, Katie served as a clinical genetic counselor and lysosomal storage disease program coordinator in the

John Taylor

John is Co-Founder, President and CEO of Aceragen, leading the effort to acquire     ACG-801 and the funding to support its development.  He has extensive experience in the orphan and rare disease field, having spent a significant portion of his career developing therapeutic products in this area. Prior to Aceragen, John co-founded and was

Alexander Solyom

Pediatrician with real-world expertise rare diseases, sphingolipid biology, inflammation and pediatric rheumatology. 13 years clinical and translational research experience, with 8 years in rare disease pharma therapeutic lifecycle development. Company, Program, and Project level leadership and accountability in international biotech startup setting including build-out, operations, due diligence and program development. Strategic planning and execution in

Atul Chopra

Atul is a Physician-Scientist and Medical Geneticist specializing in rare genetic disorders of metabolism and energy balance. These disorders typically have a genetic cause such as a single gene mutation or a larger deletion/duplication affecting many genes together. An example of his work is the discovery of asprosin, a hormone that controls appetite and glucose

Stay Connected

Join our newsletter & stay updated with all the news and events